Otsuka Pharmaceutical Development & Commercialization, Inc. (United States)
Citations 1
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial